ArticleFrontiers in immunology2026
Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization versus lenvatinib plus tislelizumab in patients with BCLC stage 0 -B hepatocellular carcinoma after radical resection.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to compare the efficacy of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) and adjuvant lenvatinib plus tislelizumab (PA-LT) in patients with Barcelona Clinic Liver Cancer (BCLC) stage 0-B hepatocellular carcinoma (HCC) who were at high risk of recurrence following radical liver resection (LR). Methods: This study retrospectively evaluated HCC patients who underwent LR at two clinical centers between January 1, 2019 and January 31, 2025. Recurrence-free survival (RFS) and overall survival (OS) were compared across three groups: LR alone, PA-TACE, and PA-LT. Propensity score matching (PSM) was conducted to reduce intergroup heterogeneity and to enhance the robustness of the results. Results: A total of 614 patients with HCC at high risk of recurrence after radical resection were included in this study. After PSM, 148, 223, and 75 patients were retained in the LR, PA-TACE, and PA-LT groups, respectively. Compared with the LR group, both the PA-TACE and PA-LT groups were associated with significant improvements in RFS and OS (all p < 0.001), and no severe adverse events were observed in either group. However, no significant differences in RFS or OS were observed between the PA-TACE and PA-LT groups (median RFS: 44.00 months (95% CI, 40.91-47.09) vs. 40.50 months (95% CI, 34.90-46.10), p = 0.086; median OS: 69.00 months (95% CI, 66.44-71.56) vs. 65.00 months (95% CI, 60.93-69.07), p = 0.572). Multivariable Cox regression analysis demonstrated that both PA-TACE and PA-LT were independently associated with improved RFS and OS. Conclusion: Both PA-TACE and PA-LT were associated with improved RFS and OS in hepatocellular carcinoma patients at high risk of recurrence after radical resection, with acceptable safety profiles. However, no significant differences were observed between the two adjuvant treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.